Browse By Title

• All
• A
• B
• C
• D
• E
• F
• G
• H
• I
• J
• K
• L
• M
• N
• O
• P
• Q
• R
• S
• T
• U
• V
• W
• X
• Y
• Z
• #

• OA2-1 - A Non-glycosylated G Protein Vaccine Protects Against Homologous and Heterologous Respiratory Syncytial Virus Challenge in Both Mice and Cotton Rats
  Favorite
  Surender Khurana, PhD – US Food and Drug Administration ### 71062###Speaker OA2-1
• OA5-3 - A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity Against Trypanosoma cruzi
  Favorite
  Nisha J. Garg, PhD, MBA – University of Texas Medical Branch ### 324349###Speaker OA5-3
• OA2-2 - “Immune Focused” Influenza Vaccines Provide Better, Long-lasting Cross-protective Immunity Compared to IIV Against Pandemic h5 & h7 Highly Pathogenic Influenza Viruses
  Favorite
  Surender Khurana, PhD – US Food and Drug Administration ### 71062###Speaker OA2-2
• S3-3 - Treating Cocaine Addiction with Viral Vector for Cholinesterase in Mice, Rats, and Rhesus Monkeys
  Favorite
  William S. Brimijoin, PhD – Mayo Clinic and Foundation ### 307027###Presenter S3-3
• OA5-2 - Advancing the Clinical Development of GEN-003, a Therapeutic Vaccine for Recurrent Genital Herpes
  Favorite
  Thomas C. Heineman, MD, PhD – Genocea Biosciences ### 324280###Speaker OA5-2
• OA6-6 - Adverse Events Following Purified Chick Embryo Cell (PCEC, Rabavert^®) Vaccine in the Vaccine Adverse Event Reporting System, 2006–2015
  Favorite
  Pedro L. Moro, MD, MPH – Centers for Disease Control and Prevention ### 79092###Speaker OA6-6
• OA6-4 - Adverse Events Following Quadrivalent Meningococcal CRM-Conjugate Vaccine Reported to the Vaccine Adverse Event Reporting System (VAERS), 2010-2015
  Favorite
  Tanya R. Myers, PhD, MSc – Emory University / Centers for Disease Control & Prevention ### 324226###Speaker OA6-4
• OA1-2 - Antibody Responses to Zika Virus in Primary and Secondary Flavivirus Infections
  Favorite
  Muktha S. Natrajan, PhD, MPH – Emory University ### 324295###Speaker OA1-2
• Awards Luncheon
  Favorite
• S2-2 - BARDA Perspective About Challenges and Opportunities in Developing EID Vaccines
  Favorite
  Ruben O. Donis, PhD – Biomedical Advanced Research and Development Authority (BARDA)
  Office of the Assistant Secretary for Preparedness and Response (ASPR)
  US Department of Health and Human Services ### 372170###Presenter S2-2
• Biology of Antibody-Enhanced Dengue Disease: Evidence of Increased Risk After CYDTDV Vaccination
  Favorite
  Scott B. Halstead, MD – International Vaccine Institute ### 78363###Featured Presenter
• S1-2 - Biology of Antibody-enhanced Dengue Disease: Evidence of Increased Risk After CYD-TDV Vaccination
  Favorite
  Scott B. Halstead, MD – International Vaccine Institute ### 78363###Presenter S1-2
• Clinical Development of Synthetic DNA Vaccines: Advances in the Technology
  Favorite
  David B. Weiner, PhD – Wistar Institute ### 307030###Featured Presenter
• S5-1 - Clinical Development of Synthetic DNA Vaccines: Advances in the Technology
  Favorite
  David B. Weiner, PhD – Wistar Institute ### 307030###Presenter S5-1
• Closing Keynote: Vaccines to Fight Emerging Infectious Diseases: Use of Novel Platform Technologies (non-CME)
  Favorite
  Phyllis A. Arthur, MBA – Biotechnology Innovation Organization ### 318682###Moderator @@@ Marc-André D'Aoust, PhD – Medicago ### 367442###Panelist @@@ David B. Weiner, PhD – Wistar Institute ### 307030###Panelist @@@ Jeffrey B. Ulmer, PhD – GSK Vaccines ### 367443###Panelist @@@ Christopher R. Heery, MD – Bavarian Nordic A/S ### 367441###Panelist
• Continental Breakfast
  Favorite
• Continental Breakfast
  Favorite
• D.A. Henderson Tribute: Legacy of Eradication Through Vaccines
  Favorite
  Bill H. Foege, MD, MPH – Emory University ### 307028###Keynote Speaker @@@ Myron M. Levine, MD, D.T.P.H. – University of Maryland School of Medicine ### 142945###Moderator
• S2-3 - Development and Approval Pathways for Vaccines to Prevent Emerging Infectious Diseases: FDA Regulatory Perspective
  Favorite
  Marion F. Gruber, PhD – US Food and Drug Administration ### 78362###Presenter S2-3
• Development and Approval Pathways for Vaccines to Prevent Emerging Infectious Diseases: FDA Regulatory Perspective
  Favorite
  Marion F. Gruber, PhD – US Food and Drug Administration ### 78362###Featured Presenter
• S3-2 - Development of Vaccines to Prevent and Treat Addiction To Cocaine and Opiate Drugs
  Favorite
  Thomas R. Kosten, MD – Baylor College of Medicine ### 307026###Presenter S3-2
• Dr. Charles Mérieux Award for Achievement in Vaccinology and Immunology
  Favorite
  Samuel L. Katz, MD – Duke University School of Medicine ### 350874###Award Recipient
• OA3-2 - Effect of Influenza Vaccination on Lymphocyte Mirna Profiles
  Favorite
  Richard B. Kennedy, PhD – Mayo Clinic and Foundation ### 211620###Speaker OA3-2
• S2-1 - Epidemiology, Disease Burden, and Population Targets For Zika Vaccine
  Favorite
  Marcos A. Espinal, MD, DrPH, MPH – Pan American Health Organization ### 316811###Presenter S2-1
• OA6-2 - Evaluating Infant Mortality and Hospitalizations After Maternal Immunization in the Vaccine Safety Datalink, 2004-2014
  Favorite
  Lakshmi Sukumaran, MD, MPH – Centers for Disease Control and Prevention ### 324250###Speaker OA6-2
• OA3-1 - Evolution of HIV-1 Env Open Trimer Conformation Driven by Peptide Fusion Inhibitor Resistance
  Favorite
  Paul W. Keller, PhD – FDA ### 211825###Speaker OA3-1
• S4-2 - FDA Licensure of a Cholera Vaccine as a Result of Pivotal Efficacy Derived from Human Challenges
  Favorite
  Wilbur H. Chen, MD, MS – University of Maryland School of Medicine ### 70833###Presenter S4-2
• OA6-5 - Feasibility of Examining Potential Mechanisms for Intussusception Following Rotavirus Vaccination in Infants 6-13 Weeks of Age
  Favorite
  Mary A. Staat, MD, MPH – Cincinnati Children's Hospital Medical Center ### 324238###Speaker OA6-5
• OA4-5 - Genetic Diversity of Nonstructural Asibi/17D Mutant Yellow Fever Viruses
  Favorite
  Natalie D. Collins, MPH, MLS (ASCP) – University of Texas Medical Branch ### 211696###Speaker OA4-5
• OA2-5 - Genome-Wide Association Mapping of the Antibody Response to Diphtheria-Tetanus-Acellular Pertussis Vaccine in Mice
  Favorite
  Yung-Yi C. Mosley, BVM, MS, PhD – Purdue University ### 324225###Speaker OA2-5
• S1-1 - Long Road to Preventing Dengue Disease by Vaccination, and Future Prospects
  Favorite
  Duane J. Gubler, ScD, MS – Duke National University of Singapore Medical School ### 307021###Presenter S1-1
• How to Get Published: Writing Effective Journal Articles
  Favorite
  Gregory A. Poland, MD – Mayo Clinic and Foundation ### 78369###Featured Presenter
• OA5-6 - Human Antibody Repertoire Following VSV-Ebola Vaccination Identifies Novel Targets and Virus Neutralizing IgM Antibodies
  Favorite
  Surender Khurana, PhD – US Food and Drug Administration ### 71062###Speaker OA5-6
• OA3-3 - Identification of Highly Conserved Influenza A HLA-A2 and HLA-DR-restricted T cell Epitopes Capable of Inducing Robust Heterotypic Protective Immunity
  Favorite
  Daniel F. Hoft, MD, PhD – Saint Louis University ### 70991###Speaker OA3-3
• OA5-4 - Immune Response and Viral Persistence in Acute Human Zika Virus Infection—a Preliminary Report
  Favorite
  Lilin Lai, MD – Emory University ### 142998###Speaker OA5-4
• OA2-6 - Immunogenicity, Safety of a Single Primary Dose of a Live Attenuated Japanese Encephalitis Recombinant Vaccine in Healthy Subjects in Vietnam
  Favorite
  Vu D. Thiem, MD, PhD – National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam ### 324263###Speaker OA2-6
• OA1-4 - Influence of e-Health Text Messages Linked to Health Portal on College Students' Influenza Vaccine Rate
  Favorite
  Catherine A. Sharbaugh, DNP, CRNP – Haverford College ### 211572###Speaker OA1-4
• S6-2 - Maintaining Public Confidence in Vaccines During a Pandemic
  Favorite
  Daniel A. Salmon, PhD – Johns Hopkins Bloomberg School of Public Health ### 316814###Presenter S6-2
• OA4-1 - Mapping the Morality of Vaccine Hesitance: Associations of Moral Foundation Values with Vaccine Hesitance
  Favorite
  Avnika B. Amin – Omer Research Group, Rollins School of Public Health, Emory University ### 324340###Speaker OA4-1
• S1-3 - Optimal use of the First Licensed Dengue Vaccine: Balancing Benefit against Potential Risks
  Favorite
  Neil M. Ferguson, PhD – Imperial College London ### 307023###Presenter S1-3
• Maurice R. Hilleman Early-Stage Career Investigator Award
  Favorite
  Jourdan A. Andersson, BS – UTMB ### 324457###Award Recipient
• S1-4 - Maximizing Benefit and Minimizing Risk for the World’s First Licensed Dengue Vaccine: CYD-TDV
  Favorite
  Timothy P. Endy, MD, MPH – State University of New York, Upstate Medical University ### 79041###Presenter S1-4
• Maximizing Benefit and Minimizing Risk for the World's First Licensed Dengue Vaccine: CYD-TDV
  Favorite
  Timothy P. Endy, MD, MPH – State University of New York, Upstate Medical University ### 79041###Featured Presenter
• OA1-3 - Modeling Reveals How Vaccination Could Significantly Reduce Hepatitis C Transmission via Syringe Sharing
  Favorite
  Marian E. Major, PhD – US Food and Drug Administration ### 324269###Speaker OA1-3
• S6-3 - Monitoring Influenza Vaccine Safety in Sentinel/Prism
  Favorite
  Katherine Yih, PhD, MPH – Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute ### 316815###Presenter S6-3
• Hilleman: A Perilous Quest to Save the World's Children
  Movie Screening followed by Q&A with Paul A. Offit, MD
  Favorite
  Paul A. Offit, MD – University of Pennsylvania Perelman School of Medicine
  Director of the Vaccine Education Center
  The Children’s Hospital of Philadelphia ### 318698###Featured Presenter
• S5-2 - mRNA-based Vaccines Against HIV and Other Pathogens
  Favorite
  Drew Weissman, MD, PhD – University of Pennsylvania ### 307032###Presenter S5-2
• OA6-1 - Nonclinical Investigations into the Reduced Effectiveness of the H1N1pdm09 Component of the Live Attenuated Influenza Vaccine
  Favorite
  Oliver E. Dibben, PhD – MedImmune ### 324398###Speaker OA6-1
• Opening Keynote: Greatest Vaccinology Discoveries of the Last Decade and Future Predictions
  Favorite
  Stanley A. Plotkin, MD – University of Pennsylvania and Vaxconsult ### 141564###Keynote Speaker @@@ Walter A. Orenstein, MD – Emory University ### 79257###Moderator
• Poster Presentations & Continental Breakfast
  Favorite
• Post-licensure Vaccine Safety Monitoring
  Favorite
  Tom T. Shimabukuro, MD, MPH, MBA – Centers for Disease Control and Prevention ### 142883###Featured Presenter
• OA3-5 - Protection of Horse Foals Against the Tuberculosis-like Pathogen Rhodococcus Equi via Conjugate Vaccine (AV0328)-induced Maternal Antibody to Poly-N-acetyl glucosamine
  Favorite
  Gerald B. Pier, PhD – Brigham & Women's Hospital ### 324328###Speaker OA3-5
• S2-4 - Rapid Development of Candidate Zika Vaccines
  Favorite
  Barney S. Graham, MD, PhD – National Institute of Allergy and Infectious Diseases/National Institutes of Health ### 79171###Presenter S2-4
• S5-4 - Recoding Structural Glycoprotein E2 in Classical Swine Fever Virus (CSFV) and Its Potential Use as a Vaccine Candidate
  Favorite
  Lauro Velazquez, DVM, MSc – Plum Island Animal Disease Center ### 316812###Presenter S5-4
• OA6-3 - Recommended Immunization Schedule and All-cause Mortality
  Favorite
  Natalie L. McCarthy, MPH – Centers for Disease Control and Prevention ### 143032###Speaker OA6-3
• Robert Austrian Memorial Lecture | Thinking Outside the Bug: An Admiral’s Reflections on the Captain of the Men of Death
  Favorite
  Anne Schuchat, MD (RADM, USPHS) ### 350869###Lecturer
• OA4-4 - Safety of MenB-FHbp, a Meningococcal Serogroup B Vaccine, in US Adolescents: Results from a Phase 3 Study
  Favorite
  John L. Perez, MD, MPH – Pfizer Vaccine Clinical Research ### 211629###Speaker OA4-4
• OA4-3 - Safety of MenB-FHbp, a Meningococcal Serogroup B Vaccine, in US Young Adults: Results from a Phase 3 Study
  Favorite
  John L. Perez, MD, MA – Pfizer Vaccine Clinical Research ### 211631###Speaker OA4-3
• OA2-3 - Sci-B-Vac, a Third Generation Hepatitis B Vaccines That Elicits Rapid and Robust Seroprotection in Adults
  Favorite
  Francisco J. Diaz Mitoma, MD, PhD, FRCPC – VBI Vaccines, Inc ### 324256###Speaker OA2-3
• S4-1 - Scientific and Regulatory Aspects of Such Studies of Vaccines
  Favorite
  Wellington Sun, MD – US Food and Drug Administration ### 141569###Presenter S4-1
• OA3-4 - Serum Antibody Profiling Following Vaccination with an Adjuvanted Thermostable Subunit Antigen Reveals a Possible Correlate of Immunity to Ricin Toxin
  Favorite
  Jennifer L. Yates, PhD – Heath Research Inc. ### 324344###Speaker OA3-4
• S5-3 - Structure-based Immunogen Design for Flavivirus Vaccines
  Favorite
  Felix A. Rey, PhD – Institut Pasteur ### 307031###Presenter S5-3
• S6-1 - Systematic Observational Method for Narcolepsy and Influenza Immunization Assessment (Somnia): Risk of Narcolepsy Following Adjuvanted 2009 H1N1 Influenza Vaccines
  Favorite
  Tom T. Shimabukuro, MD, MPH, MBA – Centers for Disease Control and Prevention ### 142883###Presenter S6-1
• Technical Tour to GSK (Pre-Registration Required)
  Location: Offsite
  Favorite
• OA1-5 - The Global Burden of Lower Respiratory Infections: Results from the Global Burden of Disease Study 2015
  Favorite
  Chris E. Troeger, MPH – University of Washington ### 324305###Speaker OA1-5
• OA1-6 - The Global Burden of Shigella and Enterotoxigenic E. coli Diarrhea
  Favorite
  Ibrahim A. Khalil, MD, MPH – University of Washington ### 324306###Speaker OA1-6
• OA2-4 - The IVAX Toolkit: Accelerating and Advancing Human and Animal Vaccine Design in Silico
  Favorite
  Frances Terry, MPH – EpiVax ### 324314###Speaker OA2-4
• OA5-5 - Tools to Characterize the Immune Response to Zika Virus (ZIKV): Reporter Virus Particles, Anti-ZIKV MAbs, and Antibody Epitope Mapping
  Favorite
  Edgar Davidson, PhD – Integral Molecular ### 211787###Speaker OA5-5
• OA4-6 - Tumorigenicity of Spontaneously Immortalized Cells Used in Vaccine Manufacture: Responsiveness to Matrigel^® as a Possible Trait for Tumorigenicity Characterization
  Favorite
  Haruhiko Murata, MD, PhD – US Food and Drug Administration ### 211717###Speaker OA4-6
• OA1-1 - Using the 4 Pillars™ Practice Transformation Program to Increase Adolescent Human Papillomavirus, Meningococcal, and Tetanus-Diphtheria-Pertussis Vaccination
  Favorite
  Richard K. Zimmerman, MD, MPH, MA, MS – University of Pittsburgh ### 71537###Speaker OA1-1
• S3-1 - Vaccination as a Means to Mitigate Drug Addiction
  Favorite
  Kim D. Janda, PhD – The Scripps Research Institute ### 307025###Presenter S3-1
• OA3-6 - Viral Vector-based Prime/Boost Regimen to Maximize Tissue-Resident Memory T Cell Responses for Therapeutic Vaccination Against HPV Cervicovaginal Neoplasia
  Favorite
  Nicolas Cuburu, PhD – National Institutes of Health National Cancer Institute ### 143142###Speaker OA3-6
• Welcome Reception & Poster Presentations
  Favorite
• OA5-1 - Willingness to Pay for an Ebola Vaccine Among a US National Sample During the 2014–2016 West African Ebola Outbreak
  Favorite
  Julia E. Painter, PhD, MPH – George Mason University ### 324283###Speaker OA5-1
• OA4-2 - Zika in the United States: Transmission and Strategies for Control
  Favorite
  L. Beryl Guterman, MSPH Candidate 2017 – Rollins School of Public Health Emory University ### 324353###Speaker OA4-2